Download PDF
Semin Neurol 2020; 40(01): 097-115
DOI: 10.1055/s-0039-3402061
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Autoimmune Vestibulocerebellar Syndromes

Ram N. Narayan
1   Department of Neurology, Barrow Neurological Institute, Phoenix, Arizona
,
Andrew McKeon
2   Departments of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
3   Department of Neurology, Mayo Clinic, Rochester, Minnesota
,
Terry D. Fife
1   Department of Neurology, Barrow Neurological Institute, Phoenix, Arizona
4   Department of Neurology, University of Arizona College of Medicine, Phoenix, Arizona
› Author Affiliations
Further Information

Publication History

Publication Date:
20 January 2020 (online)

    Permissions and Reprints

Abstract

Autoimmune disorders affecting the vestibular end organs, vestibular pathways, vestibular nuclei, and vestibulocerebellum are often underrecognized as a cause of chronic dizziness and ataxia. Autoantibodies specific for cell-surface, synaptic, and intracellular neural antigens serve as biomarkers of these disorders. This article describes the epidemiology, clinical presentation, diagnostic considerations, imaging findings, treatment, and prognosis of autoimmune disorders, in which the vestibulocerebellar syndrome is the main or presenting clinical presentation. Antibodies specific for intracellular antigenic targets described in the article are PCA-1 (Purkinje cell cytoplasmic antibody type 1, also known as anti-Yo), ANNA-1 (antinuclear neuronal antibody type 1, also known as anti-Hu), ANNA-2 (antinuclear neuronal antibody type 2, also known as anti-Ri), Ma1/2 (anti-Kelch-like 11/12 antibody), Kelch-like 11, amphiphysin, CV2 (collapsin response 2, also known as collapsin response mediator protein-5 [CRMP5]), VGCC (voltage-gated calcium channel), GAD65 (glutamic acid decarboxylase 65-kDa isoform), AP3B2 (adaptor protein 3B2, also known as anti-Nb), MAP1B (microtubule-associated protein 1B antibody, also known as anti-PCA-2), and neurochondrin antibodies. Antibodies targeting cell-surface or synaptic antigenic targets described in the article include DNER (delta/notchlike epidermal growth factor related receptor; antigen to anti-Tr), CASPR2 (contactin-associated proteinlike 2), septin-5, Homer-3, and mGluR1 (metabotropic glutamate receptor 1). The vestibulocerebellar presentation is largely indistinguishable among these conditions and is characterized by subacute onset of cerebellar symptoms over weeks to months. The diagnosis of autoimmune vestibulocerebellar syndromes is based on a combination of clinical and serological features, with a limited role for neuroimaging. Subtle eye movement abnormalities can be an early feature in many of these disorders, and therefore a meticulous vestibulo-ocular examination is essential for early and correct identification. Cancer occurrence and its type are variable and depend on the autoantibody detected and other cancer risk factors. Treatment comprises immunotherapy and cancer-directed therapy. Acute immunotherapies such as intravenous immunoglobulin, plasma exchange, and steroids are used in the initial phase, and the use of long-term immunosuppression such as rituximab may be necessary in relapsing cases. Outcomes are better if immunotherapy is started early. The neurologic prognosis depends on multiple factors.

Keywords

autoimmune cerebellar ataxia - central nervous system - vestibulocerebellar syndromes - autoimmune encephalitis - downbeat nystagmus
 

  • References

  • 1 Francis DA, Bronstein AM, Rudge P, du Boulay EP. The site of brainstem lesions causing semicircular canal paresis: an MRI study. J Neurol Neurosurg Psychiatry 1992; 55 (06) 446-449
    CrossrefPubMedGoogle Scholar
  • 2 Carter S, Sciarra D, Merritt HH. The course of multiple sclerosis as determined by autopsy proven cases. Res Publ Assoc Res Nerv Ment Dis 1950; 28: 471-511
    PubMedGoogle Scholar
  • 3 Gass A, Steinke W, Schwartz A, Hennerici MG. High resolution magnetic resonance imaging in peripheral vestibular dysfunction in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998; 65 (06) 945
    CrossrefPubMedGoogle Scholar
  • 4 Frohman EM, Kramer PD, Dewey RB, Kramer L, Frohman TC. Benign paroxysmal positioning vertigo in multiple sclerosis: diagnosis, pathophysiology and therapeutic techniques. Mult Scler 2003; 9 (03) 250-255
    CrossrefPubMedGoogle Scholar
  • 5 Herrera WG. Vestibular and other balance disorders in multiple sclerosis. Differential diagnosis of disequilibrium and topognostic localization. Neurol Clin 1990; 8 (02) 407-420
    CrossrefPubMedGoogle Scholar
  • 6 McKeon A, Pittock SJ. Paraneoplastic encephalomyelopathies: pathology and mechanisms. Acta Neuropathol 2011; 122 (04) 381-400
    CrossrefPubMedGoogle Scholar
  • 7 Dalmau J, Geis C, Graus F. Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system. Physiol Rev 2017; 97 (02) 839-887
    CrossrefPubMedGoogle Scholar
  • 8 Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology 2011; 77 (02) 179-189
    CrossrefPubMedGoogle Scholar
  • 9 Peterson K, Rosenblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 1992; 42 (10) 1931-1937
    CrossrefPubMedGoogle Scholar
  • 10 Shams'ili S, Grefkens J, de Leeuw B. , et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 2003; 126 (Pt 6): 1409-1418
    CrossrefPubMedGoogle Scholar
  • 11 Gilmore CP, Elliott I, Auer D, Maddison P. Diffuse cerebellar MR imaging changes in anti-Yo positive paraneoplastic cerebellar degeneration. J Neurol 2010; 257 (03) 490-491
    CrossrefPubMedGoogle Scholar
  • 12 van Broekhoven PC, Frens MA, Sillevis Smitt PA, van der Geest JN. Eye movements as a marker for cerebellar damage in paraneoplastic neurological syndromes. Parkinsonism Relat Disord 2007; 13 (Suppl. 03) S296-S300
    CrossrefPubMedGoogle Scholar
  • 13 Wray SH, Dalmau J, Chen A, King S, Leigh RJ. Paraneoplastic disorders of eye movements. Ann N Y Acad Sci 2011; 1233: 279-284
    CrossrefPubMedGoogle Scholar
  • 14 Tohid H. Anti-glutamic acid decarboxylase antibody positive neurological syndromes. Neurosciences (Riyadh) 2016; 21 (03) 215-222
    PubMedGoogle Scholar
  • 15 Jen JC, Lopez I, Baloh RW. Opsoclonus: clinical and immunological features. J Neurol Sci 2012; 320 (1-2): 61-65
    CrossrefPubMedGoogle Scholar
  • 16 Armangué T, Sabater L, Torres-Vega E. , et al. Clinical and immunological features of opsoclonus-myoclonus syndrome in the era of neuronal cell surface antibodies. JAMA Neurol 2016; 73 (04) 417-424
    CrossrefPubMedGoogle Scholar
  • 17 Sahu JK, Prasad K. The opsoclonus–myoclonus syndrome. Pract Neurol 2011; 11 (03) 160-166
    CrossrefPubMedGoogle Scholar
  • 18 Sharma P, Mazumdar B, Chatterjee P. Cerebellar hypermetabolism on 18F-FDG PET/CT with normal MRI in a case of paraneoplastic cerebellar degeneration with negative antibodies. Rev Esp Med Nucl Imagen Mol 2015; 34 (01) 79-80
    PubMedGoogle Scholar
  • 19 Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med 2003; 349 (16) 1543-1554
    CrossrefPubMedGoogle Scholar
  • 20 Darnell RB, Posner JB. Paraneoplastic syndromes affecting the nervous system. Semin Oncol 2006; 33 (03) 270-298
    CrossrefPubMedGoogle Scholar
  • 21 Graus F, Keime-Guibert F, Reñe R. , et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001; 124 (Pt 6): 1138-1148
    CrossrefPubMedGoogle Scholar
  • 22 Kannoth S. Paraneoplastic neurologic syndrome: a practical approach. Ann Indian Acad Neurol 2012; 15 (01) 6-12
    CrossrefPubMedGoogle Scholar
  • 23 Keime-Guibert F, Graus F, Fleury A. , et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 2000; 68 (04) 479-482
    CrossrefPubMedGoogle Scholar
  • 24 Vernino S, O'Neill BP, Marks RS, O'Fallon JR, Kimmel DW. Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro-oncol 2004; 6 (01) 55-62
    PubMedGoogle Scholar
  • 25 Bradley WH, Dottino PR, Rahaman J. Paraneoplastic cerebellar degeneration in ovarian carcinoma: case report with review of immune modulation. Int J Gynecol Cancer 2008; 18 (06) 1364-1367
    CrossrefPubMedGoogle Scholar
  • 26 Jones AL, Flanagan EP, Pittock SJ. , et al. Responses to and outcomes of treatment of autoimmune cerebellar ataxia in adults. JAMA Neurol 2015; 72 (11) 1304-1312
    CrossrefPubMedGoogle Scholar
  • 27 Venkatraman A, Opal P. Paraneoplastic cerebellar degeneration with anti-Yo antibodies - a review. Ann Clin Transl Neurol 2016; 3 (08) 655-663
    CrossrefPubMedGoogle Scholar
  • 28 Rojas I, Graus F, Keime-Guibert F. , et al. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 2000; 55 (05) 713-715
    CrossrefPubMedGoogle Scholar
  • 29 Psimaras D, Carpentier AF, Rossi C. ; PNS Euronetwork. Cerebrospinal fluid study in paraneoplastic syndromes. J Neurol Neurosurg Psychiatry 2010; 81 (01) 42-45
    CrossrefPubMedGoogle Scholar
  • 30 Greenlee JE, Brashear HR. Antibodies to cerebellar Purkinje cells in patients with paraneoplastic cerebellar degeneration and ovarian carcinoma. Ann Neurol 1983; 14 (06) 609-613
    CrossrefPubMedGoogle Scholar
  • 31 Corradi JP, Yang C, Darnell JC, Dalmau J, Darnell RB. A post-transcriptional regulatory mechanism restricts expression of the paraneoplastic cerebellar degeneration antigen cdr2 to immune privileged tissues. J Neurosci 1997; 17 (04) 1406-1415
    CrossrefPubMedGoogle Scholar
  • 32 Rodriguez M, Truh LI, O'Neill BP, Lennon VA. Autoimmune paraneoplastic cerebellar degeneration: ultrastructural localization of antibody-binding sites in Purkinje cells. Neurology 1988; 38 (09) 1380-1386
    CrossrefPubMedGoogle Scholar
  • 33 Aboul-Enein F, Höftberger R, Buxhofer-Ausch V. , et al. Neocortical neurones may be targeted by immune attack in anti-Yo paraneoplastic syndrome. Neuropathol Appl Neurobiol 2008; 34 (02) 248-252
    CrossrefPubMedGoogle Scholar
  • 34 Verschuuren J, Chuang L, Rosenblum MK. , et al. Inflammatory infiltrates and complete absence of Purkinje cells in anti-Yo-associated paraneoplastic cerebellar degeneration. Acta Neuropathol 1996; 91 (05) 519-525
    CrossrefPubMedGoogle Scholar
  • 35 Monstad SE, Storstein A, Dørum A. , et al. Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique. Clin Exp Immunol 2006; 144 (01) 53-58
    CrossrefPubMedGoogle Scholar
  • 36 Scheid R, Voltz R, Briest S, Kluge R, von Cramon DY. Clinical insights into paraneoplastic cerebellar degeneration. J Neurol Neurosurg Psychiatry 2006; 77 (04) 529-530
    CrossrefPubMedGoogle Scholar
  • 37 Candler PM, Hart PE, Barnett M, Weil R, Rees JH. A follow up study of patients with paraneoplastic neurological disease in the United Kingdom. J Neurol Neurosurg Psychiatry 2004; 75 (10) 1411-1415
    CrossrefPubMedGoogle Scholar
  • 38 Henson RA, Hoffman HL, Urich H. Encephalomyelitis with carcinoma. Brain 1965; 88 (03) 449-464
    CrossrefPubMedGoogle Scholar
  • 39 Henson RA, Urich H. Peripheral neuropathy and carcinoma. Proc Aust Assoc Neurol 1968; 5 (02) 399-402
    PubMedGoogle Scholar
  • 40 Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology 1998; 50 (03) 652-657
    CrossrefPubMedGoogle Scholar
  • 41 Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu--associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) 1992; 71 (02) 59-72
    PubMedGoogle Scholar
  • 42 Pradat PF, Uchuya M, Fontaine B, Lubetzki C. Pure cerebellar syndrome associated with anti-Hu antibodies [in French]. Rev Neurol (Paris) 1995; 151 (05) 341-343
    PubMedGoogle Scholar
  • 43 Huemer F, Melchardt T, Tränkenschuh W. , et al. Anti-Hu antibody associated paraneoplastic cerebellar degeneration in head and neck cancer. BMC Cancer 2015; 15: 996
    CrossrefPubMedGoogle Scholar
  • 44 Saiz A, Bruna J, Stourac P. , et al. Anti-Hu-associated brainstem encephalitis. J Neurol Neurosurg Psychiatry 2009; 80 (04) 404-407
    PubMedGoogle Scholar
  • 45 Nguyen-tat M, Pohl J, Günter E. , et al. Severe paraneoplastic gastroparesis associated with anti-Hu antibodies preceding the manifestation of small-cell lung cancer. Z Gastroenterol 2008; 46 (03) 274-278
    Article in Thieme ConnectPubMedGoogle Scholar
  • 46 Bechich S, Graus F, Arboix A, Isidro A, Martí M, Rosell F. Anti-Hu-associated paraneoplastic sensory neuropathy and breast cancer. J Neurol 2000; 247 (07) 552-553
    CrossrefPubMedGoogle Scholar
  • 47 Manley GT, Smitt PS, Dalmau J, Posner JB. Hu antigens: reactivity with Hu antibodies, tumor expression, and major immunogenic sites. Ann Neurol 1995; 38 (01) 102-110
    CrossrefPubMedGoogle Scholar
  • 48 King PH, Redden D, Palmgren JS, Nabors LB, Lennon VA. Hu antigen specificities of ANNA-I autoantibodies in paraneoplastic neurological disease. J Autoimmun 1999; 13 (04) 435-443
    CrossrefPubMedGoogle Scholar
  • 49 Darnell RB. RNA regulation in neurologic disease and cancer. Cancer Res Treat 2010; 42 (03) 125-129
    CrossrefPubMedGoogle Scholar
  • 50 Senties-Madrid H, Vega-Boada F. Paraneoplastic syndromes associated with anti-Hu antibodies. Isr Med Assoc J 2001; 3 (02) 94-103
    Google Scholar
  • 51 Roberts WK, Deluca IJ, Thomas A. , et al. Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells. J Clin Invest 2009; 119 (07) 2042-2051
    PubMedGoogle Scholar
  • 52 Bernal F, Graus F, Pifarré A, Saiz A, Benyahia B, Ribalta T. Immunohistochemical analysis of anti-Hu-associated paraneoplastic encephalomyelitis. Acta Neuropathol 2002; 103 (05) 509-515
    CrossrefPubMedGoogle Scholar
  • 53 Sillevis Smitt P, Grefkens J, de Leeuw B. , et al. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol 2002; 249 (06) 745-753
    CrossrefPubMedGoogle Scholar
  • 54 Luque FA, Furneaux HM, Ferziger R. , et al. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol 1991; 29 (03) 241-251
    CrossrefPubMedGoogle Scholar
  • 55 Vernino S, Lennon VA. New Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity. Ann Neurol 2000; 47 (03) 297-305
    CrossrefPubMedGoogle Scholar
  • 56 Pittock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol 2003; 53 (05) 580-587
    CrossrefPubMedGoogle Scholar
  • 57 Goyal MK, Bhatkar S, Modi M. , et al. Anti-Ri antibody-mediated paraneoplastic cerebellar degeneration: a rare, treatable yet poorly recognized entity. Neurol India 2016; 64 (05) 1033-1035
    CrossrefPubMedGoogle Scholar
  • 58 Mitchell AN, Bakhos CT, Zimmerman EA. Anti-Ri-associated paraneoplastic brainstem cerebellar syndrome with coexisting limbic encephalitis in a patient with mixed large cell neuroendocrine lung carcinoma. J Clin Neurosci 2015; 22 (02) 421-423
    CrossrefPubMedGoogle Scholar
  • 59 Tay JK, Miller J, Joshi A, Athey RJ. Anti-Ri-associated paraneoplastic cerebellar and brainstem degenerative syndrome. J R Coll Physicians Edinb 2012; 42 (03) 221-224
    CrossrefPubMedGoogle Scholar
  • 60 Ohmer R, Golnik KC, Richards AI, Kosmorsky GS. Ophthalmoplegia associated with the anti-Ri antibody. J Neuroophthalmol 1999; 19 (04) 246-248
    PubMedGoogle Scholar
  • 61 Casado JL, Gil-Peralta A, Graus F, Arenas C, Lopez JM, Alberca R. Anti-Ri antibodies associated with opsoclonus and progressive encephalomyelitis with rigidity. Neurology 1994; 44 (08) 1521-1522
    CrossrefPubMedGoogle Scholar
  • 62 Dalmau J, Posner JB. Neurologic paraneoplastic antibodies (anti-Yo; anti-Hu; anti-Ri): the case for a nomenclature based on antibody and antigen specificity. Neurology 1994; 44 (12) 2241-2246
    CrossrefPubMedGoogle Scholar
  • 63 Neumann H, Medana IM, Bauer J, Lassmann H. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci 2002; 25 (06) 313-319
    CrossrefPubMedGoogle Scholar
  • 64 Dalmau J, Gultekin SH, Voltz R. , et al. Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. Brain 1999; 122 (Pt 1): 27-39
    CrossrefPubMedGoogle Scholar
  • 65 Ortega Suero G, Sola-Valls N, Escudero D, Saiz A, Graus F. Anti-Ma and anti-Ma2-associated paraneoplastic neurological syndromes. Neurologia 2018; 33 (01) 18-27
    CrossrefPubMedGoogle Scholar
  • 66 Bustos M, Berger H, Hannoush ZC, Ayala A, Freire R, Kargi AY. Anti-Ma-1 and Anti-Ma-2 antibodies in isolated fatal hypothalamitis. J Endocr Soc 2018; 2 (02) 106-111
    CrossrefPubMedGoogle Scholar
  • 67 Hoffmann LA, Jarius S, Pellkofer HL. , et al. Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: 22 newly diagnosed patients and review of previous cases. J Neurol Neurosurg Psychiatry 2008; 79 (07) 767-773
    CrossrefPubMedGoogle Scholar
  • 68 Rosenfeld MR, Eichen JG, Wade DF, Posner JB, Dalmau J. Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol 2001; 50 (03) 339-348
    CrossrefPubMedGoogle Scholar
  • 69 Garcia-Reitboeck P, Thompson G, Johns P, Al Wahab Y, Omer S, Griffin C. Upbeat nystagmus in anti-Ma2 encephalitis. Pract Neurol 2014; 14 (01) 36-38
    CrossrefPubMedGoogle Scholar
  • 70 Souza PV, Bortholin T, Pinto WB, Santos AJ. Progressive hearing loss and cerebellar ataxia in anti-Ma2-associated autoimmune encephalitis. Arq Neuropsiquiatr 2017; 75 (01) 74-75
    CrossrefPubMedGoogle Scholar
  • 71 Prüss H, Voltz R, Gelderblom H. , et al. Spontaneous remission of anti-Ma associated paraneoplastic mesodiencephalic and brainstem encephalitis. J Neurol 2008; 255 (02) 292-294
    CrossrefPubMedGoogle Scholar
  • 72 De Camilli P, Thomas A, Cofiell R. , et al. The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of Stiff-Man syndrome with breast cancer. J Exp Med 1993; 178 (06) 2219-2223
    CrossrefPubMedGoogle Scholar
  • 73 Coppens T, Van den Bergh P, Duprez TJ, Jeanjean A, De Ridder F, Sindic CJ. Paraneoplastic rhombencephalitis and brachial plexopathy in two cases of amphiphysin auto-immunity. Eur Neurol 2006; 55 (02) 80-83
    CrossrefPubMedGoogle Scholar
  • 74 Pittock SJ, Lucchinetti CF, Parisi JE. , et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol 2005; 58 (01) 96-107
    CrossrefPubMedGoogle Scholar
  • 75 Moon J, Lee ST, Shin JW. , et al. Non-stiff anti-amphiphysin syndrome: clinical manifestations and outcome after immunotherapy. J Neuroimmunol 2014; 274 (1-2): 209-214
    CrossrefPubMedGoogle Scholar
  • 76 McKeon A, Pittock SJ, Lennon VA. Stiff-person syndrome with amphiphysin antibodies: distinctive features of a rare disease. Neurology 2009; 73 (24) 2132 , author reply 2133
    CrossrefPubMedGoogle Scholar
  • 77 Antoine JC, Honnorat J, Vocanson C. , et al. Posterior uveitis, paraneoplastic encephalomyelitis and auto-antibodies reacting with developmental protein of brain and retina. J Neurol Sci 1993; 117 (1-2): 215-223
    CrossrefPubMedGoogle Scholar
  • 78 Rogemond V, Honnorat J. Anti-CV2 autoantibodies and paraneoplastic neurological syndromes. Clin Rev Allergy Immunol 2000; 19 (01) 51-59
    CrossrefPubMedGoogle Scholar
  • 79 Aliprandi A, Terruzzi A, Rigamonti A. , et al. Paraneoplastic cerebellar degeneration with anti-CV2/CRMP5 antibodies and prostate adenocarcinoma. Neurol Sci 2015; 36 (08) 1501-1503
    CrossrefPubMedGoogle Scholar
  • 80 de la Sayette V, Bertran F, Honnorat J, Schaeffer S, Iglesias S, Defer G. Paraneoplastic cerebellar syndrome and optic neuritis with anti-CV2 antibodies: clinical response to excision of the primary tumor. Arch Neurol 1998; 55 (03) 405-408
    CrossrefPubMedGoogle Scholar
  • 81 Medrano V, Sempere AP, González E. Paraneoplastic ataxia associated to anti CV2 antibodies [in Spanish]. Rev Neurol 2003; 36 (02) 131-133
    PubMedGoogle Scholar
  • 82 Honnorat J, Trouillas P, Thivolet C, Aguera M, Belin MF. Autoantibodies to glutamate decarboxylase in a patient with cerebellar cortical atrophy, peripheral neuropathy, and slow eye movements. Arch Neurol 1995; 52 (05) 462-468
    CrossrefPubMedGoogle Scholar
  • 83 Baizabal-Carvallo JF, Alonso-Juarez M. Cerebellar disease associated with anti-glutamic acid decarboxylase antibodies: review. J Neural Transm (Vienna) 2017; 124 (10) 1171-1182
    CrossrefPubMedGoogle Scholar
  • 84 Dalakas MC. Stiff person syndrome: advances in pathogenesis and therapeutic interventions. Curr Treat Options Neurol 2009; 11 (02) 102-110
    CrossrefPubMedGoogle Scholar
  • 85 Hadjivassiliou M, Boscolo S, Tongiorgi E. , et al. Cerebellar ataxia as a possible organ-specific autoimmune disease. Mov Disord 2008; 23 (10) 1370-1377
    CrossrefPubMedGoogle Scholar
  • 86 Matsumoto S, Kusuhara T, Nakajima M, Ouma S, Takahashi M, Yamada T. Acute attacks and brain stem signs in a patient with glutamic acid decarboxylase autoantibodies. J Neurol Neurosurg Psychiatry 2002; 73 (03) 345-346
    CrossrefPubMedGoogle Scholar
  • 87 Ariño H, Gresa-Arribas N, Blanco Y. , et al. Cerebellar ataxia and glutamic acid decarboxylase antibodies: immunologic profile and long-term effect of immunotherapy. JAMA Neurol 2014; 71 (08) 1009-1016
    CrossrefPubMedGoogle Scholar
  • 88 Ariño H, Höftberger R, Gresa-Arribas N. , et al. Paraneoplastic neurological syndromes and glutamic acid decarboxylase antibodies. JAMA Neurol 2015; 72 (08) 874-881
    CrossrefPubMedGoogle Scholar
  • 89 Saiz A, Blanco Y, Sabater L. , et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain 2008; 131 (Pt 10): 2553-2563
    CrossrefPubMedGoogle Scholar
  • 90 Saiz A, Arpa J, Sagasta A. , et al. Autoantibodies to glutamic acid decarboxylase in three patients with cerebellar ataxia, late-onset insulin-dependent diabetes mellitus, and polyendocrine autoimmunity. Neurology 1997; 49 (04) 1026-1030
    CrossrefPubMedGoogle Scholar
  • 91 Baizabal-Carvallo JF, Alonso-Juarez M. Vertical nystagmus associated with glutamic acid decarboxylase antibodies responding to cyclophosphamide. J Neuroimmunol 2018; 317: 5-7
    CrossrefPubMedGoogle Scholar
  • 92 Martins AI, Carvalho JN, Amorim AM, Geraldo A, Eggenberger E, Lemos J. Disabling central paroxysmal positioning upbeat nystagmus and vertigo associated with the presence of anti-glutamic acid decarboxylase antibodies. J Neuroophthalmol 2018; 38 (01) 32-35
    CrossrefPubMedGoogle Scholar
  • 93 Ances BM, Dalmau JO, Tsai J, Hasbani MJ, Galetta SL. Downbeating nystagmus and muscle spasms in a patient with glutamic-acid decarboxylase antibodies. Am J Ophthalmol 2005; 140 (01) 142-144
    CrossrefPubMedGoogle Scholar
  • 94 Antonini G, Nemni R, Giubilei F. , et al. Autoantibodies to glutamic acid decarboxylase in downbeat nystagmus. J Neurol Neurosurg Psychiatry 2003; 74 (07) 998-999
    CrossrefPubMedGoogle Scholar
  • 95 Zivotofsky AZ, Siman-Tov T, Gadoth N, Gordon CR. A rare saccade velocity profile in stiff-person syndrome with cerebellar degeneration. Brain Res 2006; 1093 (01) 135-140
    CrossrefPubMedGoogle Scholar
  • 96 Bhandari HS. Presentation of opsoclonus myoclonus ataxia syndrome with glutamic acid decarboxylase antibodies. BMJ Case Rep 2012; 2012: pii: bcr2012006339
    PubMedGoogle Scholar
  • 97 Markakis I, Alexiou E, Xifaras M, Gekas G, Rombos A. Opsoclonus-myoclonus-ataxia syndrome with autoantibodies to glutamic acid decarboxylase. Clin Neurol Neurosurg 2008; 110 (06) 619-621
    CrossrefPubMedGoogle Scholar
  • 98 Shaikh AG, Wilmot G. Opsoclonus in a patient with increased titers of anti-GAD antibody provides proof for the conductance-based model of saccadic oscillations. J Neurol Sci 2016; 362: 169-173
    CrossrefPubMedGoogle Scholar
  • 99 Pietrini V, Pavesi G, Andreetta F. Miller Fisher syndrome with positivity of anti-GAD antibodies. Clin Neurol Neurosurg 2013; 115 (08) 1479-1481
    CrossrefPubMedGoogle Scholar
  • 100 Nanri K, Niwa H, Mitoma H. , et al. Low-titer anti-GAD-antibody-positive cerebellar ataxia. Cerebellum 2013; 12 (02) 171-175
    CrossrefPubMedGoogle Scholar
  • 101 Hadjivassiliou M, Aeschlimann D, Grünewald RA, Sanders DS, Sharrack B, Woodroofe N. GAD antibody-associated neurological illness and its relationship to gluten sensitivity. Acta Neurol Scand 2011; 123 (03) 175-180
    PubMedGoogle Scholar
  • 102 McKeon A, Tracy JA. GAD65 neurological autoimmunity. Muscle Nerve 2017; 56 (01) 15-27
    CrossrefPubMedGoogle Scholar
  • 103 Dinkel K, Meinck HM, Jury KM, Karges W, Richter W. Inhibition of gamma-aminobutyric acid synthesis by glutamic acid decarboxylase autoantibodies in stiff-man syndrome. Ann Neurol 1998; 44 (02) 194-201
    CrossrefPubMedGoogle Scholar
  • 104 Fenalti G, Buckle AM. Structural biology of the GAD autoantigen. Autoimmun Rev 2010; 9 (03) 148-152
    CrossrefPubMedGoogle Scholar
  • 105 Lohmann T, Londei M, Hawa M, Leslie RD. Humoral and cellular autoimmune responses in stiff person syndrome. Ann N Y Acad Sci 2003; 998: 215-222
    CrossrefPubMedGoogle Scholar
  • 106 Holmøy T, Skorstad G, Røste LS, Scheie D, Alvik K. Stiff person syndrome associated with lower motor neuron disease and infiltration of cytotoxic T cells in the spinal cord. Clin Neurol Neurosurg 2009; 111 (08) 708-712
    CrossrefPubMedGoogle Scholar
  • 107 Alexopoulos H, Dalakas MC. Immunology of stiff person syndrome and other GAD-associated neurological disorders. Expert Rev Clin Immunol 2013; 9 (11) 1043-1053
    CrossrefPubMedGoogle Scholar
  • 108 Manto MU, Laute MA, Aguera M, Rogemond V, Pandolfo M, Honnorat J. Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases. Ann Neurol 2007; 61 (06) 544-551
    CrossrefPubMedGoogle Scholar
  • 109 Majumdar S, Mallick BN. Increased levels of tyrosine hydroxylase and glutamic acid decarboxylase in locus coeruleus neurons after rapid eye movement sleep deprivation in rats. Neurosci Lett 2003; 338 (03) 193-196
    CrossrefPubMedGoogle Scholar
  • 110 Dalakas MC. The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies. J Neurol 2005; 252 (Suppl. 01) I19-I25
    CrossrefPubMedGoogle Scholar
  • 111 Georgieva Z, Parton M. Cerebellar ataxia and epilepsy with anti-GAD antibodies: treatment with IVIG and plasmapheresis. BMJ Case Rep 2014; 2014: bcr2013202314
    PubMedGoogle Scholar
  • 112 Virgilio R, Corti S, Agazzi P. , et al. Effect of steroid treatment in cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies. J Neurol Neurosurg Psychiatry 2009; 80 (01) 95-96
    CrossrefPubMedGoogle Scholar
  • 113 Saidha S, Murphy S, Ronayne A, McCarthy P, Hennessy MJ, Counihan T. Treatment of anti-glutamic acid decarboxylase antibody-associated limbic encephalitis with mycophenolate mofetil. J Neurol 2010; 257 (06) 1035-1038
    CrossrefPubMedGoogle Scholar
  • 114 Balint B, Meinck HM. Pragmatic treatment of stiff person spectrum disorders. Mov Disord Clin Pract (Hoboken) 2018; 5 (04) 394-401
    CrossrefPubMedGoogle Scholar
  • 115 Jarius S, Scharf M, Begemann N. , et al. Antibodies to the inositol 1,4,5-trisphosphate receptor type 1 (ITPR1) in cerebellar ataxia. J Neuroinflammation 2014; 11: 206
    CrossrefPubMedGoogle Scholar
  • 116 Alfugham N, Gadoth A, Lennon VA. , et al. ITPR1 autoimmunity: frequency, neurologic phenotype, and cancer association. Neurol Neuroimmunol Neuroinflamm 2017; 5 (01) e418
    PubMedGoogle Scholar
  • 117 Jarius S, Wildemann B. ‘Medusa-head ataxia’: the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 1: anti-mGluR1, anti-Homer-3, anti-Sj/ITPR1 and anti-CARP VIII. J Neuroinflammation 2015; 12: 166
    CrossrefPubMedGoogle Scholar
  • 118 Dent MA, Raisman G, Lai FA. Expression of type 1 inositol 1,4,5-trisphosphate receptor during axogenesis and synaptic contact in the central and peripheral nervous system of developing rat. Development 1996; 122 (03) 1029-1039
    PubMedGoogle Scholar
  • 119 Jarius S, Wandinger KP, Horn S, Heuer H, Wildemann B. A new Purkinje cell antibody (anti-Ca) associated with subacute cerebellar ataxia: immunological characterization. J Neuroinflammation 2010; 7: 21
    CrossrefPubMedGoogle Scholar
  • 120 Jarius S, Wildemann B. ‘Medusa head ataxia’: the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 2: anti-PKC-gamma, anti-GluR-delta2, anti-Ca/ARHGAP26 and anti-VGCC. J Neuroinflammation 2015; 12: 167
    CrossrefPubMedGoogle Scholar
  • 121 Doss S, Nümann A, Ziegler A. , et al. Anti-Ca/anti-ARHGAP26 antibodies associated with cerebellar atrophy and cognitive decline. J Neuroimmunol 2014; 267 (1-2): 102-104
    CrossrefPubMedGoogle Scholar
  • 122 Mandel-Brehm C, Dubey D, Kryzer TJ. , et al. Kelch-like protein 11 antibodies in seminoma-associated paraneoplastic encephalitis. N Engl J Med 2019; 381 (01) 47-54
    CrossrefPubMedGoogle Scholar
  • 123 Gadoth A, Kryzer TJ, Fryer J, McKeon A, Lennon VA, Pittock SJ. Microtubule-associated protein 1B: novel paraneoplastic biomarker. Ann Neurol 2017; 81 (02) 266-277
    CrossrefPubMedGoogle Scholar
  • 124 Benarroch EE. Dynamics of microtubules and their associated proteins: recent insights and clinical implications. Neurology 2016; 86 (20) 1911-1920
    CrossrefPubMedGoogle Scholar
  • 125 Villarroel-Campos D, Gonzalez-Billault C. The MAP1B case: an old MAP that is new again. Dev Neurobiol 2014; 74 (10) 953-971
    CrossrefPubMedGoogle Scholar
  • 126 Bloom GS, Luca FC, Vallee RB. Microtubule-associated protein 1B: identification of a major component of the neuronal cytoskeleton. Proc Natl Acad Sci U S A 1985; 82 (16) 5404-5408
    CrossrefPubMedGoogle Scholar
  • 127 Tanner SL, Franzen R, Jaffe H, Quarles RH. Evidence for expression of some microtubule-associated protein 1B in neurons as a plasma membrane glycoprotein. J Neurochem 2000; 75 (02) 553-562
    PubMedGoogle Scholar
  • 128 Calvert R, Anderton BH. A microtubule-associated protein (MAP1) which is expressed at elevated levels during development of the rat cerebellum. EMBO J 1985; 4 (05) 1171-1176
    CrossrefPubMedGoogle Scholar
  • 129 Albert ML, Darnell RB. Paraneoplastic neurological degenerations: keys to tumour immunity. Nat Rev Cancer 2004; 4 (01) 36-44
    CrossrefPubMedGoogle Scholar
  • 130 Darnell RB, Furneaux HM, Posner JB. Antiserum from a patient with cerebellar degeneration identifies a novel protein in Purkinje cells, cortical neurons, and neuroectodermal tumors. J Neurosci 1991; 11 (05) 1224-1230
    CrossrefPubMedGoogle Scholar
  • 131 Newman LS, McKeever MO, Okano HJ, Darnell RB. Beta-NAP, a cerebellar degeneration antigen, is a neuron-specific vesicle coat protein. Cell 1995; 82 (05) 773-783
    CrossrefPubMedGoogle Scholar
  • 132 Jarius S, Wildemann B. ‘Medusa head ataxia’: the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 3: anti-Yo/CDR2, anti-Nb/AP3B2, PCA-2, anti-Tr/DNER, other antibodies, diagnostic pitfalls, summary and outlook. J Neuroinflammation 2015; 12: 168
    CrossrefPubMedGoogle Scholar
  • 133 Miske R, Gross CC, Scharf M. , et al. Neurochondrin is a neuronal target antigen in autoimmune cerebellar degeneration. Neurol Neuroimmunol Neuroinflamm 2016; 4 (01) e307
    PubMedGoogle Scholar
  • 134 Weihua Z, Haitao R, Fang F, Xunzhe Y, Jing W, Hongzhi G. Neurochondrin antibody serum positivity in three cases of autoimmune cerebellar ataxia. Cerebellum 2019
    PubMedGoogle Scholar
  • 135 Becker EB, Zuliani L, Pettingill R. , et al. Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxia. J Neurol Neurosurg Psychiatry 2012; 83 (04) 437-440
    CrossrefPubMedGoogle Scholar
  • 136 Fabbri M, Giannoccaro MP, Leta C, Donadio V, Avoni P, Liguori R. Non-paraneoplastic ataxia in a patient with contactin-associated protein-2 antibodies and benign course. Eur J Neurol 2015; 22 (05) e62-e63
    CrossrefPubMedGoogle Scholar
  • 137 Allen NM, McKeon A, O'Rourke DJ, O'Meara A, King MD. Excessive blinking and ataxia in a child with occult neuroblastoma and voltage-gated potassium channel antibodies. Pediatrics 2012; 129 (05) e1348-e1352
    CrossrefPubMedGoogle Scholar
  • 138 Balint B, Regula JU, Jarius S, Wildemann B. Caspr2 antibodies in limbic encephalitis with cerebellar ataxia, dyskinesias and myoclonus. J Neurol Sci 2013; 327 (1-2): 73-74
    CrossrefPubMedGoogle Scholar
  • 139 López Chiriboga AS, Pittock S. Episodic ataxia in CASPR2 autoimmunity. Neurol Neuroimmunol Neuroinflamm 2018; 6 (02) e536
    PubMedGoogle Scholar
  • 140 Tan KM, Lennon VA, Klein CJ, Boeve BF, Pittock SJ. Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology 2008; 70 (20) 1883-1890
    CrossrefPubMedGoogle Scholar
  • 141 Zalewski NL, Lennon VA, Lachance DH, Klein CJ, Pittock SJ, Mckeon A. P/Q- and N-type calcium-channel antibodies: oncological, neurological, and serological accompaniments. Muscle Nerve 2016; 54 (02) 220-227
    CrossrefPubMedGoogle Scholar
  • 142 Frey J, Murray A. Autoimmune encephalitis with elevated N-type calcium channel antibodies as a multiple sclerosis mimic. Mult Scler Relat Disord 2018; 26: 201-203
    CrossrefPubMedGoogle Scholar
  • 143 Bekircan-Kurt CE, Derle Çiftçi E, Kurne AT, Anlar B. Voltage gated calcium channel antibody-related neurological diseases. World J Clin Cases 2015; 3 (03) 293-300
    PubMedGoogle Scholar
  • 144 Martín-García E, Mannara F, Gutiérrez-Cuesta J. , et al. Intrathecal injection of P/Q type voltage-gated calcium channel antibodies from paraneoplastic cerebellar degeneration cause ataxia in mice. J Neuroimmunol 2013; 261 (1-2): 53-59
    CrossrefPubMedGoogle Scholar
  • 145 Pinto A, Gillard S, Moss F. , et al. Human autoantibodies specific for the alpha1A calcium channel subunit reduce both P-type and Q-type calcium currents in cerebellar neurons. Proc Natl Acad Sci U S A 1998; 95 (14) 8328-8333
    CrossrefPubMedGoogle Scholar
  • 146 Rigamonti A, Lauria G, Stanzani L, Mantero V, Andreetta F, Salmaggi A. Non-paraneoplastic voltage-gated calcium channels antibody-mediated cerebellar ataxia responsive to IVIG treatment. J Neurol Sci 2014; 336 (1-2): 169-170
    CrossrefPubMedGoogle Scholar
  • 147 Trotter JL, Hendin BA, Osterland CK. Cerebellar degeneration with Hodgkin disease. An immunological study. Arch Neurol 1976; 33 (09) 660-661
    CrossrefPubMedGoogle Scholar
  • 148 Bernal F, Shams'ili S, Rojas I. , et al. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. Neurology 2003; 60 (02) 230-234
    CrossrefPubMedGoogle Scholar
  • 149 Ypma PF, Wijermans PW, Koppen H, Sillevis Smitt PA. Paraneoplastic cerebellar degeneration preceding the diagnosis of Hodgkin's lymphoma. Neth J Med 2006; 64 (07) 243-247
    PubMedGoogle Scholar
  • 150 Bruylant K, Crols R, Humbel RL, Appel B, De Deyn PP. Probably anti-Tr associated paraneoplastic cerebellar degeneration as initial presentation of a squamous cell carcinoma of the lung. Clin Neurol Neurosurg 2006; 108 (04) 415-417
    CrossrefPubMedGoogle Scholar
  • 151 Graus F, Dalmau J, Valldeoriola F. , et al. Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin's disease. J Neuroimmunol 1997; 74 (1-2): 55-61
    CrossrefPubMedGoogle Scholar
  • 152 de Graaff E, Maat P, Hulsenboom E. , et al. Identification of delta/notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration. Ann Neurol 2012; 71 (06) 815-824
    CrossrefPubMedGoogle Scholar
  • 153 Tohgo A, Eiraku M, Miyazaki T. , et al. Impaired cerebellar functions in mutant mice lacking DNER. Mol Cell Neurosci 2006; 31 (02) 326-333
    CrossrefPubMedGoogle Scholar
  • 154 Eiraku M, Hirata Y, Takeshima H, Hirano T, Kengaku M. Delta/notch-like epidermal growth factor (EGF)-related receptor, a novel EGF-like repeat-containing protein targeted to dendrites of developing and adult central nervous system neurons. J Biol Chem 2002; 277 (28) 25400-25407
    CrossrefPubMedGoogle Scholar
  • 155 Greene M, Lai Y, Baella N, Dalmau J, Lancaster E. Antibodies to Delta/notch-like epidermal growth factor-related receptor in patients with anti-Tr, paraneoplastic cerebellar degeneration, and Hodgkin lymphoma. JAMA Neurol 2014; 71 (08) 1003-1008
    CrossrefPubMedGoogle Scholar
  • 156 Honorat JA, Lopez-Chiriboga AS, Kryzer TJ. , et al. Autoimmune septin-5 cerebellar ataxia. Neurol Neuroimmunol Neuroinflamm 2018; 5 (05) e474
    CrossrefPubMedGoogle Scholar
  • 157 Erratum: autoimmune septin-5 cerebellar ataxia. Neurol Neuroimmunol Neuroinflamm 2018; 6 (01) e534
    PubMedGoogle Scholar
  • 158 Lopez-Chiriboga AS, Komorowski L, Kümpfel T. , et al. Metabotropic glutamate receptor type 1 autoimmunity: clinical features and treatment outcomes. Neurology 2016; 86 (11) 1009-1013
    CrossrefPubMedGoogle Scholar
  • 159 Gollion C, Dupouy J, Roberts M. , et al. Reversible myoclonus-ataxia encephalitis related to anti-mGLUR1 autoantibodies. Mov Disord 2019; 34 (03) 438-439
    CrossrefPubMedGoogle Scholar
  • 160 Coesmans M, Smitt PA, Linden DJ. , et al. Mechanisms underlying cerebellar motor deficits due to mGluR1-autoantibodies. Ann Neurol 2003; 53 (03) 325-336
    CrossrefPubMedGoogle Scholar
  • 161 Yoshikura N, Kimura A, Fukata M. , et al. Long-term clinical follow-up of a patient with non-paraneoplastic cerebellar ataxia associated with anti-mGluR1 autoantibodies. J Neuroimmunol 2018; 319: 63-67
    CrossrefPubMedGoogle Scholar
  • 162 Joubert B, Honnorat J. Nonparaneoplastic autoimmune cerebellar ataxias. Curr Opin Neurol 2019; 32 (03) 484-492
    CrossrefPubMedGoogle Scholar
  • 163 Zuliani L, Sabater L, Saiz A, Baiges JJ, Giometto B, Graus F. Homer 3 autoimmunity in subacute idiopathic cerebellar ataxia. Neurology 2007; 68 (03) 239-240
    CrossrefPubMedGoogle Scholar
  • 164 Höftberger R, Sabater L, Ortega A, Dalmau J, Graus F. Patient with homer-3 antibodies and cerebellitis. JAMA Neurol 2013; 70 (04) 506-509
    CrossrefPubMedGoogle Scholar